2021-01-CAP: The PROGRESS Trial – Continued Access (A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement)
Principal Investigator: Benjamin Galper, MD
Contact: Kara Wright, RN, BSN, Clinical Research Nurse, 240-632-4285
ClinicalTrials.gov ID: NCT04889872
A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization with Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients with Symptomatic Aortic Valve Stenosis undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement: The COMPLETE TAVR Study
Principal Investigator: Benjamin Galper, MD
Contact: Kara Wright, RN, BSN, Clinical Research Nurse, 240-632-4285
ClinicalTrials.gov ID: NCT04634240
No Clinical Trials
“Coming Soon”
(it’s not yet open for enrollment, but we anticipate it to be open soon)
CDI02: A Randomized, Double-Blind, Placebo-Controlled Study of LMN-201 for Prevention of difficile infection recurrence (RePreve)
Principal Investigator: David Yoho, MD
Contact: Kara Wright, RN, BSN, Clinical Research Nurse, 240-632-4285
ClinicalTrials.gov ID: NCT05330182
VX21-147-301: A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Principal Investigator: PI: Tulsi Mehta, MD
Contact: Laura Ofiara, BS, Clinical Research Coordinator, 227-229-8779, Kazzmine Moses, DC, Clinical Research Coordinator, 240-632-4285
ClinicalTrials.gov ID: NCT05312879
No Clinical Trials
Lung-MAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT03851445
S1900G: A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT05642572
NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT05174169
NRG-CC005: FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT05080673
S1900K: A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT06031688
S1800E: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT06616584
A222004: A Randomized Phase III Trial of Olanzapine versus Megestrol Acetate for Cancer-Associated Anorexia
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT04939090
NRG-BR009: Ph. III Adjuvant Trial Evaluating the Addition of Adj. Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT05879926
S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT03418961
A012103: OptimICE-PCR: De-Escalation of Therapy in Early Stage TNBC Patients who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT05812807
A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT06671912
NRG-C011: Cognitive Training for Cancer Related Cancer Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Associate Director of Clinical Trials, 240-632-4285
ClinicalTrials.gov ID: NCT05896189
Temporarily on hold